Movement Disorders Overview

Principles

Definition

Movement disorders is a field of research and clinical practice within neurology focused on the study, diagnosis, and management of conditions characterized by abnormal control of body movements. This area investigates the diverse etiologies, underlying pathophysiology, clinical manifestations, and therapeutic approaches for hyperkinetic (excessive) and hypokinetic (reduced) movement abnormalities.

Ontological type

Therapeutic Strategies

Etiology and Genetics

Pathophysiological Mechanisms

Key developments

Key Figures

Circuit Foundations era

The Circuit Foundations era (1953–1977) consolidated circuit-based models of motor control, tying tremor, oculomotor abnormalities, and parkinsonian features to integrated basal ganglia, brainstem, and cortical circuits. Arvid Carlsson's demonstration that dopamine is a key transmitter in the basal ganglia and that dopaminergic pharmacology can modulate movement anchored the functional circuit view in identifiable neurochemical pathways. George M. Cotzias' successful introduction of L-DOPA therapy in Parkinson's disease provided a pivotal pharmacological probe that linked circuit dysfunction to symptomatic relief and validated circuit-based hypotheses. David Marsden's neurophysiological and clinical work helped delineate basal ganglia-thalamocortical loops and framed bradykinesia, tremor, and other motor disorders as products of circuit dysfunction.

Phenotype-driven Targeting era

Mahlon R. DeLong[1] of University of California, San Francisco[3] and Johns Hopkins University[4] stands as a central figure in the phenotype-driven targeting era of movement disorders. His key contribution, highlighted by the 1999 Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus[6], linked abnormal basal ganglia activity to dystonia phenotypes and informed targeted neuromodulation. Jerrold L. Vitek[2] of University of California, San Francisco[3] and University of Minnesota[5] contributed to advancing the era's phenotype-to-target framework. His work with the 1999 Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus[6] reinforced a paradigm in which electrophysiology and standardized phenotyping guide target selection, enabling durable symptom control.

Biomarker-driven Translation era

Heiko Braak [1] is associated with the University of Pennsylvania [3] and the Medical University of Vienna [4] during the Biomarker-driven Translation era. His key contributions in this era, as reflected by the paper Staging of brain pathology related to sporadic Parkinson’s disease [7], include the development of staging frameworks that advanced biomarker-informed patient stratification and mechanistic understanding. William G. Ondo [2] is associated with Harvard University [5] and Stanford University [6] during this era. His key contribution in this era, as reflected by the paper Restless legs syndrome/Willis–Ekbom disease diagnostic criteria [8], established consensus criteria that advanced diagnostic standardization and biomarker-informed patient stratification for movement disorders.